The therapeutic efficacy of the AZT and IFN combination in ATL presumably reflects the inhibition of RT-related functions.
HTLV-1–RT activity from short-term cultured PBMCs may represent a predictive correlate of clinical response to AZT/IFN in ATL patients.
The human T-lymphotropic virus type 1 (HTLV-1) retrovirus1 is the etiological agent of adult T-cell leukemia/lymphoma (ATL), HTLV-1–associated myelopathy/tropical spastic paraparesis, and a number of inflammatory diseases.2 ATL is an aggressive malignancy occurring mostly in adults 30 to 50 years after HTLV-1 infection. ATL cells are characterized by low virus expression in vivo. The prognosis is very poor, ranging from 6 to 24 months median survival. Chemotherapy has little long-term efficacy in ATL. Allogeneic stem cell transplantation can result in long-term disease control but few patients can be successfully transplanted.3
Antiretrovirals with activity against HIV-1, such as zidovudine (3′-azido-2′,3′-dideoxythymidine [AZT]) and tenofovir, and new phosphonated compounds, efficiently block HTLV-1 transmission in vitro,4-7 whereas HTLV-1 was resistant to lamivudine.8
Two preliminary phase 2 studies using the combination of AZT and interferon-α (IFN-α) reported an unexpectedly high response rate, particularly in previously untreated acute ATL patients.9-11 The efficacy of this combination was confirmed, with minor differences, in various clinical trials and in a worldwide meta-analysis.12-16 These results changed the clinical management of ATL.16-19 However, there is yet no direct proof of an antiviral mechanism of action of the drug combination, due to the absence of virological markers that strictly correlate with disease status.
In this study, we investigated HTLV-1 reverse transcriptase (RT) activity and other virological parameters, in samples from short-term cultures of peripheral blood mononuclear cells (PBMCs) collected from ATL patients before and after therapy.
Patients and samples
This retrospective cohort study was carried out using PBMCs collected and immediately frozen from 10 HTLV-1+ ATL patients. For 7 patients, PBMCs were collected both before therapy and 1 to 2 years after initiation of antiviral therapy with AZT (900 mg per day) and IFN (5 million IU/m2 per day).13 For 3 patients, only diagnostic samples were available (characteristics of the patients and further details on sample processing are available as supplemental Methods).
Cell cultures and quantification of virological parameters
PBMCs were cryopreserved until use. After 24 hours, and after 7 and 10 days in culture, supernatants were harvested and frozen, and the cell concentration was adjusted to the initial value with fresh medium. We were unable to set up cell cultures from 1 of the 7 treated patients, who was therefore excluded from further analysis.
HTLV-1 expression was evaluated in RNA isolated from cells collected after 7 days in culture, using the RNAqueous-Micro kit (Ambion), by quantitative real-time polymerase chain reaction (PCR) for tax/rex expression performed in triplicate as previously described.20
HTLV-1 p19 was detected in supernatants from ATL cultures, using an HTLV-1 p19 Gag antigen capture enzyme-linked immunosorbent assay (ZeptoMetrix Corp) according to the manufacturer’s protocols. p19 concentrations in the supernatants harvested after 24 hours of culture did not differ from those in supernatants from the same culture harvested later on. Consequently, supernatants collected at different times from the same culture were pooled.
HTLV-1 RT activity was quantified in crude whole lysates of the same pools of supernatants used for p19 detection, using our recently described cell-free HTLV-1 RT assay.7 First, we tested the reliability of our HTLV-1 RT assay using serial dilution of MT2 supernatants mimicking conditions of those from ATL PBMC cultures. DNA extracted from cells harvested after 10 days in culture was used for HTLV-1 clonality analysis of samples collected before and after therapy for 1 representative responder patient and 1 nonresponder patient (details of the assays and of the preliminary tests are given in supplemental Methods).
Results and discussion
AZT and IFN therapy decreased HTLV-1 tax/rex transcripts
We quantified tax/rex transcripts by quantitative real-time PCR. At the time of collection of the posttherapy sample, 4 patients (ATL 1, 2, 3, 6) were in complete response and 1 (ATL 7) was in good partial response to AZT/IFN, whereas 1 patient with acute ATL (ATL 4) was resistant to this therapy (supplemental Results). The expression of tax/rex in PBMC cultures from ATL 1, 2, 6, and 7 was variably inhibited in comparison with pretreatment samples, whereas minimal change was seen in ATL 3 and no change was observed in ATL 4 (Figure 1A). Expression of tax/rex in diagnostic samples from ATL 8, 9, and 10 was comparable to pretreatment samples of treated ATL patients (Figure 1B).
AZT and IFN therapy reduced p19 release
Supernatants from PBMC cultures of treated patients ATL 1, 2 and 3, 6, and 7 exhibited a decrease of p19 production by 75% to 88% in comparison with those of the same patients collected before treatment (Figure 1C). Conversely, no difference occurred in ATL 4 before vs after treatment. Levels of p19 in samples from newly diagnosed ATL patients (ATL 8, 9, 10) were similar to pretreatment samples of treated patients (Figure 1D).
AZT and IFN therapy completely inhibited RT activity and modified the clonality pattern in samples from responding ATL patients
RT preparations consisting of samples containing 5 to 25 pg of p19 in 10 μL, following readjustment from the crude whole lysates of supernatants, were used as a source of RT in the in vitro quantitative real-time PCR assay. The amplification products were assayed by densitometry (Figure 2A). In all samples, the plateau of amplification was reached in the presence of 20 to 25 pg of the p19 equivalent amount of RT preparation. However, the RT activity detected in 20-pg p19 equivalent RT preparations from ATL samples before treatment was around 30% less than that detected in the same p19 equivalent amount of MT-2 supernatants. The RT preparations from ATL patients (1, 2, 3, 6, 7) before treatment exhibited an activity similar to newly diagnosed ATL patients (8, 9, 10) (Figure 2B). The RT activity was completely inhibited in samples collected after therapy in ATL 1, 2, 3, 6, and 7 patients at all p19 equivalent amounts tested (Figure 2A). Conversely, the RT activity detected in the sample from the ATL 4 patient after treatment was similar to that of the same patient before treatment.
Whereas no difference was observed in the HTLV-1 proviral loads, the clonality analysis showed a dramatic shift from a monoclonal pretherapy pattern to a more polyclonal posttherapy pattern in samples from the responder patient 7, with oligoclonality index (OCI) decreasing from 0.97 to 0.64; no change was observed in nonresponder patient 4 with OCI at 0.94 and 0.95 before and after therapy, respectively (Figure 2C).
The mechanisms underlying the therapeutic efficacy of the combination of AZT and IFN in ATL patients are still elusive. Several reports suggest that either AZT or IFN alone can control HTLV-1 infection in vitro and in animal models. Nevertheless, no clear evidence was provided concerning the effect of the AZT/IFN combination on virus infectivity in ATL patients. In the present study, we report for the first time that long-term in vivo therapy with AZT and IFN caused complete inhibition of RT activity, reductions in 2 other virological parameters, and a dramatic change in the clonality pattern, in short-term cultures of PBMCs from ATL patients who responded to therapy. A previous study on PBMCs freshly collected from ATL patients showed no evidence of RT-mediated viral replication.19 Hence, we assume that short-term culture allowed a more substantial recovery of virus release in the supernatants.
The findings we report here suggest that HTLV-1 replication, presumably in HTLV-1–infected nonleukemic cells, might contribute to the evolution of ATL. Furthermore, the HTLV-1 RT assay may be considered as predictive of response to therapy or early relapse; this conclusion needs to be validated by a large prospective study.
The full-text version of this article contains a data supplement.
This work was supported by the Italian Ministry of University and Research, Projects of National Interest (PRIN; A.B. and B.M.); Istituto Superiore di Sanità, AIDS Project; the University of Rome Tor Vergata (B.M.); and the University of Messina and the Institute of Translational Pharmacology (A. Mastino).
Contribution: B.M., A. Mastino, and A.B. searched for literature, designed the study, interpreted the data, and wrote the paper; A.B., O.H., and A. Marçais enrolled the patients and followed the clinical study; E.B. performed the primary cell cultures and viral load of fresh ATL mononuclear cells; C.F. and F.M.-M. carried on the HTLV-1 RT assay and were in charge of virus preparation and virus capture assay; S.G. and E.V. carried out the real-time PCR assay; E.B., C.F., and B.M. performed elaboration and graphical representation of the data; and J.T. and C.R.B. performed the clonality analysis.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Antonio Mastino, Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Via F. Stagno d’Alcontres 31, 98166 Messina, Italy; e-mail: firstname.lastname@example.org; and Ali Bazarbachi, Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon; e-mail: email@example.com.
A. Mastino and A.B. contributed equally to this study as joint senior authors.